Knowledge of, and attitude towards, the treatment of hepatitis C in people who inject drugs.

Publisher: BioMed Central Country of Publication: England NLM ID: 101153624 Publication Model: Electronic Cited Medium: Internet ISSN: 1477-7517 (Electronic) Linking ISSN: 14777517 NLM ISO Abbreviation: Harm Reduct J Subsets: MEDLINE

Original Publication: [London] : BioMed Central, c2004-

Substance Abuse, Intravenous*/complications ; Substance Abuse, Intravenous*/psychology ; Health Knowledge, Attitudes, Practice* ; Hepatitis C*/drug therapy ; Hepatitis C*/complications ; Antiviral Agents*/therapeutic use; Humans ; Male ; Female ; Middle Aged ; Adult ; Germany/epidemiology ; Opiate Substitution Treatment/methods

Background: Direct acting antivirals (DAAs) as a curative treatment of hepatitis C have been available for several years and have replaced interferon-containing therapies. However, treatment rates of people who inject drugs (PWID) are declining in Germany, putting the elimination of hepatitis C by 2030 at risk. This study aimed at elucidating the knowledge of, and attitude towards, hepatitis C treatment in a clinical sample of PWID.
Methods: Participants were recruited between February 2019 and October 2020 at two opioid agonist therapy (OAT) clinics and two in-patient drug detoxification wards. Based on the European Addiction Severity Index (Europ-ASI), a standardized interview focusing on: sociodemographic data, drug history, risky behavior, infection with hepatitis C virus (HCV) and HIV, and previous experience with HCV treatment was carried out. In addition, participants filled in a questionnaire evaluating 13 statements relating to HCV treatment (right/wrong) and 15 statements on their personal 'pros and cons' views to start such a treatment assessed with the means of a 6-point Likert scale.
Results: A total of 153 patients (average age 45 years, male 78%; 106 (69.3%) currently in opioid maintenance treatment, 47 (30.7%) currently admitted to an inpatient detoxification) with an opioid use disorder were investigated. All of them reported having injected drugs at least once in their lives; 97 participants (63.3%) stated that they had been previously diagnosed with HCV infection. Among them, 27/97 patients (27.8%) reported a previous treatment with interferon; 27/97 (27.8%) with DAAs; and 32/97 (33.0%) reported a currently active hepatitis C. Most patients knew about the availability and efficacy of DAAs. However, DAAs' low rate of side effects, their short treatment duration, and their replacement of interferon, were not correctly evaluated by up to 50.3% of patients. 25-40% of 32 patients with currently active hepatitis C prioritized handling of social and other medical issues, e.g., reduction of heroin use, over treatment of hepatitis C.
Conclusions: Although current levels of risky behavior have reportedly been reduced by active PWID over the past few years, educational and motivational interventions to increase hepatitis C treatment uptake should address the gaps in patients' knowledge.
(© 2024. The Author(s).)

BMC Infect Dis. 2019 Jul 23;19(1):655. (PMID: 31337339)
Addiction. 2023 Sep;118(9):1624-1648. (PMID: 37005867)
Int J Drug Policy. 2021 Feb;88:103019. (PMID: 33160152)
Harm Reduct J. 2020 Jan 10;17(1):7. (PMID: 31924208)
Ann Intern Med. 2017 May 02;166(9):637-648. (PMID: 28319996)
Clin Infect Dis. 2013 Aug;57 Suppl 2:S97-104. (PMID: 23884073)
Drug Alcohol Rev. 2019 Feb;38(2):177-184. (PMID: 30652363)
J Subst Abuse Treat. 2019 May;100:45-51. (PMID: 30898327)
Eur J Gastroenterol Hepatol. 2010 Mar;22(3):270-7. (PMID: 20425880)
Risk Manag Healthc Policy. 2021 Nov 15;14:4639-4647. (PMID: 34815725)
BMC Public Health. 2016 Sep 05;16:927. (PMID: 27595567)
N Engl J Med. 2002 Sep 26;347(13):975-82. (PMID: 12324553)
J Subst Use. 2020;25(4):343-349. (PMID: 33041652)
J Viral Hepat. 2022 Aug;29(8):588-595. (PMID: 35545901)
Harm Reduct J. 2014 Jan 14;11:1. (PMID: 24422784)
Clin Infect Dis. 2020 May 23;70(11):2355-2365. (PMID: 31513710)
Addict Sci Clin Pract. 2021 Aug 12;16(1):52. (PMID: 34384494)
Clin Infect Dis. 2021 Jul 1;73(1):e107-e118. (PMID: 32447375)
J Hepatol. 2023 Feb;78(2):452. (PMID: 36464532)
BMC Infect Dis. 2019 Mar 4;19(1):222. (PMID: 30832608)
J Hepatol. 2013 Sep;59(3):434-41. (PMID: 23669289)
BMC Public Health. 2023 Jun 1;23(1):1038. (PMID: 37259073)
BMC Infect Dis. 2014;14 Suppl 6:S16. (PMID: 25252742)
Cochrane Database Syst Rev. 2017 Sep 18;9:CD012143. (PMID: 28922704)
J Hepatol. 2020 Nov;73(5):1170-1218. (PMID: 32956768)
Hepatol Med Policy. 2016 Sep 01;1:8. (PMID: 30288312)
Nephrol Dial Transplant. 2003 Aug;18(8):1573-80. (PMID: 12897097)
Dtsch Arztebl Int. 2019 Mar 1;116(9):137-143. (PMID: 30961791)
Subst Use Misuse. 2010;45(1-2):176-89. (PMID: 20025446)
Lancet. 2016 Sep 10;388(10049):1081-1088. (PMID: 27394647)
Can J Gastroenterol Hepatol. 2014 Sep;28(8):445-51. (PMID: 25229466)
J Viral Hepat. 2018 Jul;25(7):762-770. (PMID: 29369467)
Liver Int. 2023 Jun;43(6):1195-1203. (PMID: 36825358)
Lancet Glob Health. 2017 Dec;5(12):e1192-e1207. (PMID: 29074409)
Int J Drug Policy. 2021 Oct;96:103247. (PMID: 33853727)
Addiction. 2010 May;105(5):844-59. (PMID: 20219055)
N Engl J Med. 2011 Jun 23;364(25):2429-38. (PMID: 21696309)

Keywords: Attitude; Direct acting antiviral drugs; Hepatitis C; Knowledge; Opioid use disorder

0 (Antiviral Agents)

Date Created: 20240828 Date Completed: 20240829 Latest Revision: 20240902

20240902

PMC11351267

10.1186/s12954-024-01068-w

39198822